Naproxen
| Evidence Level: L5 | Predicted Indications: 4 |
Table of Contents
Naproxen: From Pain and Inflammation to Brachydactyly-Syndactyly Syndrome
One-Sentence Summary
Naproxen is a widely marketed non-steroidal anti-inflammatory drug (NSAID) used for pain and inflammation. The TxGNN model predicts it may be effective for brachydactyly-syndactyly syndrome, a congenital limb malformation. This prediction currently has 0 clinical trials and 0 publications behind it, so it is a model output only.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Pain and inflammation (general drug knowledge; the US label text is not included in the supplied data) |
| Predicted New Indication | Brachydactyly-syndactyly syndrome |
| TxGNN Prediction Score | 99.35% |
| Evidence Level | L5 |
| US Market Status | ✓ Marketed |
| Number of NDAs | 20 |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Currently, detailed mechanism of action data is not available in the supplied record. Naproxen is a non-selective COX-1/COX-2 inhibitor. Its efficacy in pain and inflammation is well established, and it works by reducing prostaglandin production.
Brachydactyly-syndactyly syndromes are congenital limb malformations with a developmental or genetic basis. Prostaglandin inhibition is not known to modify them, and NSAIDs would not be expected to correct a structural developmental defect. No established mechanistic link was identified.
The high score most likely reflects proximity in the knowledge graph, not a biological rationale. The other top-ranked predictions show the same pattern:
- Colobomatous microphthalmia-rhizomelic dysplasia syndrome (99.22%)
- Acromesomelic dysplasia, Hunter-Thompson type (99.17%)
- Brachyolmia-amelogenesis imperfecta syndrome (99.06%)
All are rare congenital skeletal or developmental disorders with no trials or literature, and none has a plausible link to COX inhibition.
Clinical Trial Evidence
Currently no related clinical trials registered.
Literature Evidence
Currently no related literature available.
US Market Information
The supplied data lists no approved indication text for these authorizations. The table shows 5 of the 20 authorizations.
| Authorization Number | Product Name | Dosage Form | Manufacturer |
|---|---|---|---|
| NDA020204 | Aleve | Tablet | Lil’ Drug Store Products, Inc |
| ANDA208363 | Naproxen Sodium | Capsule, liquid filled | Care One (American Sales Company) |
| ANDA091416 | Naproxen | Tablet | NuCare Pharmaceuticals, Inc. |
| ANDA212517 | Naproxen | Tablet | Preferred Pharmaceuticals, Inc. |
| ANDA200629 | Naproxen Sodium | Tablet, film coated | Aurobindo Pharma Limited |
All listed products are oral: tablets, film-coated or coated tablets, and liquid-filled capsules.
Safety Considerations
Please refer to the package insert for safety information.
Conclusion and Next Steps
Decision: Hold
Rationale: The prediction is supported only by a knowledge-graph score, with no trials, no publications, and no plausible mechanism linking COX inhibition to a congenital limb malformation. The evidence level is L5, and the candidate remains at the initial screening stage (S0).
To proceed, the following is needed:
- The FDA package insert warnings and contraindications, which block safety screening
- Mechanism of action data from DrugBank
- A biological rationale connecting prostaglandin or COX pathways to the pathogenesis of the predicted disease
- Any supporting preclinical, case-level, or clinical evidence
- Route compatibility assessment, which is still pending
This report is for research reference only and does not constitute medical advice. Repurposing candidates require clinical validation before any clinical use.
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.